AstraZeneca PLC (LON:AZN) Receives Consensus Rating of “Moderate Buy” from Analysts

by · The Cerbat Gem

Shares of AstraZeneca PLC (LON:AZN – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is £150.

Several equities research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a £117 target price on shares of AstraZeneca in a research report on Tuesday. Berenberg Bank dropped their price target on shares of AstraZeneca from £160 to £150 and set a “buy” rating on the stock in a research note on Tuesday. Royal Bank Of Canada reissued an “outperform” rating and set a £145 price objective on shares of AstraZeneca in a report on Tuesday, September 8th. Citigroup boosted their price objective on shares of AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Finally, Jefferies Financial Group restated a “buy” rating and issued a £175 target price on shares of AstraZeneca in a report on Wednesday, September 9th.

Get Our Latest Stock Analysis on AZN

AstraZeneca Stock Up 0.7%

Shares of LON AZN opened at £121.96 on Wednesday. The business has a 50-day moving average of £122.39 and a two-hundred day moving average of £134.90. The company has a market capitalization of £189.15 billion, a price-to-earnings ratio of 18.26, a price-to-earnings-growth ratio of 0.86 and a beta of 0.20. AstraZeneca has a 1 year low of £107.84 and a 1 year high of £157.32. The company has a debt-to-equity ratio of 64.10, a current ratio of 0.89 and a quick ratio of 0.59.

Key AstraZeneca News

Here are the key news stories impacting AstraZeneca this week:

  • Positive Sentiment: Chair Michel Demaré purchased 2,500 AstraZeneca shares for approximately £303,000 at an average price of £121.21. The transaction may be viewed as a sign of confidence from a senior insider. AstraZeneca Chair Michel Demaré Buys Additional Shares in the Company
  • Positive Sentiment: AstraZeneca and Daiichi Sankyo reported that Enhertu improved progression-free survival by six months in a first-line trial for HER2-mutant non-small-cell lung cancer. The result supports the commercial and clinical potential of the companies’ oncology partnership. AstraZeneca’s Enhertu Improves PFS By 6 Months
  • Neutral Sentiment: Deutsche Bank upgraded AstraZeneca to “hold,” while maintaining a £117 price target. The change is modestly more favorable in rating terms but still indicates limited near-term upside at the bank’s valuation. Deutsche Bank Upgrades AstraZeneca to Hold
  • Neutral Sentiment: Berenberg retained a “buy” rating but reduced its price target from £160 to £150, suggesting continued long-term confidence alongside more cautious expectations.
  • Negative Sentiment: AstraZeneca’s Etcamah combination failed to meet the primary endpoint in the Phase III SERENA-4 trial. The setback could weaken expectations for the treatment’s future revenue contribution and is likely the most significant near-term pressure on the shares. AstraZeneca SERENA-4 Trial Fails to Meet Primary Objective

Insider Buying and Selling

In related news, insider Michel Demare purchased 2,500 shares of AstraZeneca stock in a transaction that occurred on Monday, September 14th. The stock was purchased at an average cost of £121.21 per share, with a total value of £303,025. 0.15% of the stock is owned by corporate insiders.

AstraZeneca Company Profile

(Get Free Report)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Featured Stories